Terms: = Kidney tumors AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Clinical Outcome
11 results:
1. Biphasic squamoid alveolar papillary renal cell carcinoma: A unique papillary renal cell carcinoma with distinctive morphology, immunophenotype and molecular genetic features.
Li Y; Wu X; Yang J; Jiang Y; Li Y; Zhang W; Yu W
Pathol Res Pract; 2022 Nov; 239():154120. PubMed ID: 36201928
[TBL] [Abstract] [Full Text] [Related]
2. Factors affecting prognosis of the patients with severe hyponatremia.
Turkmen E; Karatas A; Altindal M
Nefrologia (Engl Ed); 2022; 42(2):196-202. PubMed ID: 36153916
[TBL] [Abstract] [Full Text] [Related]
3. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Dizman N; Meza L; Bergerot P; Alcantara M; Dorff T; Lyou Y; Frankel P; Cui Y; Mira V; Llamas M; Hsu J; Zengin Z; Salgia N; Salgia S; Malhotra J; Chawla N; Chehrazi-Raffle A; Muddasani R; Gillece J; Reining L; Trent J; Takahashi M; Oka K; Higashi S; Kortylewski M; Highlander SK; Pal SK
Nat Med; 2022 Apr; 28(4):704-712. PubMed ID: 35228755
[TBL] [Abstract] [Full Text] [Related]
4. Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.
Zhang L; Zha Z; Qu W; Zhao H; Yuan J; Feng Y; Wu B
BMC Cancer; 2018 Sep; 18(1):870. PubMed ID: 30176824
[TBL] [Abstract] [Full Text] [Related]
5. Correlation of c-met Expression with PD-L1 Expression in metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Kammerer-Jacquet SF; Medane S; Bensalah K; Bernhard JC; Yacoub M; Dupuis F; Ravaud A; Verhoest G; Mathieu R; Peyronnet B; Brunot A; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Target Oncol; 2017 Aug; 12(4):487-494. PubMed ID: 28550387
[TBL] [Abstract] [Full Text] [Related]
6. [c-met Oncogene in Renal Cell Carcinomas].
Erlmeier F; Weichert W; Autenrieth M; Ivanyi P; Hartmann A; Steffens S
Aktuelle Urol; 2016 Dec; 47(6):475-479. PubMed ID: 28006830
[TBL] [Abstract] [Full Text] [Related]
7. Targeting met and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract] [Full Text] [Related]
8. A Phase I/II Trial of BNC105P with Everolimus in metastatic Renal Cell Carcinoma.
Pal S; Azad A; Bhatia S; Drabkin H; Costello B; Sarantopoulos J; Kanesvaran R; Lauer R; Starodub A; Hauke R; Sweeney CJ; Hahn NM; Sonpavde G; Richey S; Breen T; Kremmidiotis G; Leske A; Doolin E; Bibby DC; Simpson J; Iglesias J; Hutson T
Clin Cancer Res; 2015 Aug; 21(15):3420-7. PubMed ID: 25788492
[TBL] [Abstract] [Full Text] [Related]
9. Diameter-axial-polar nephrometry: integration and optimization of R.E.N.A.L. and centrality index scoring systems.
Simmons MN; Hillyer SP; Lee BH; Fergany AF; Kaouk J; Campbell SC
J Urol; 2012 Aug; 188(2):384-90. PubMed ID: 22698624
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic factors in a prospective series of papillary renal cell carcinoma.
Gontero P; Ceratti G; Guglielmetti S; Andorno A; Terrone C; Bonvini D; Faggiano F; Tizzani A; Frea B; Valente G
BJU Int; 2008 Sep; 102(6):697-702. PubMed ID: 18489525
[TBL] [Abstract] [Full Text] [Related]
11. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract] [Full Text] [Related]
